Comparison of Two Once-Daily Regimens with a Regimen Consisting of Nelfinavir, Didanosine, and Stavudine in Antiretroviral Therapy-Naïve Adults: 48-Week Results from the Antiretroviral Regimen Evaluation Study (ARES)

REFERENCES

• The EACS Euroguidelines Group. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS. 2003;17\(suppl 2):S3–26.
   Google Scholar
• Gazzard B. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med. 2005;6\(suppl 2):1–61.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services (DHHS)/Panel on Clinical Practices for Treatment of HIV Infection. Guide-lines for the use of antiretroviral angents in HIV-1-infected adults and adolescents (April 7,2005). Available at: http://AIDSinfo.nih.gov. Accessed August 5, 2005.
   Google Scholar
• Lowe SH, Prins JM, Lange JMA. Antiretroviral therapy in previously untreated adults infected with the human immu-nodeficiency virus type 1: established and potential deter-minants of virological outcome. Neth J Med. 2004;62(11): 424–440.
   PubMed Web of Science ®Google Scholar
• Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001; 15(11):1369–1377.
   PubMed Web of Science ®Google Scholar
• Bartlett JA, Fath MJ, DeMasi R, et al. An updated system-atic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. Presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22–25, 2005; Boston, Massachussetts. Abstract 586.
   Google Scholar
• National Institute of Allergy and Infectious Diseases (NIAID), Division of AIDS (DAIDS), Regulatory Compliance Center (RCC). Table for grading severity of adult adverse experiences. August 1992. Available at: http://rcc.tech-res-intl.com/DAIDS%2ORCC%20Forms/TB_ToxicityTables_Adult_TRP_v01a.pdf. Accessed August 23, 2005.
   Google Scholar
• Weverling GJ, Lange JMA, Jurriaans S, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS. 1998;12:F117–F122.
   PubMed Web of Science ®Google Scholar
• Shafer R, Robbins G, Smeaton L, et al. Antiretroviral strate-gies in naive HIV+ subjects: comparison of 4-drug versus sequential 3-drug regimens (ACTG 384). In: Program and abstracts of the 14th International AIDS Conference; July 7–12, 2002; Barcelona, Spain. Abstract LbOr20B.
   Google Scholar
• Robbins G, Shafer R, Smeaton L, et al. Antiretroviral strate-gies in naive HIV+ subjects: comparison of sequential 3-drug regimens (ACTG 384). In: Program and abstracts of the 14th International AIDS Conference; July 7–12, 2002; Barcelona, Spain. Abstract LbOr20A.
   Google Scholar
• Whitehead J. The Design and Analysis of Sequential Clini-cal Trials. 2nd ed., rev. Chichester: Wiley; 1997.
   Google Scholar
• The University of Reading. PEST 4: Operating ManuaL United Kingdom: Author; 2000.
   Google Scholar
• Lowe SH, Prins JM, van der Lelie J, Lange JM. Does highly active antiretroviral therapy induce sickle cell crises? AIDS. 2002 ;16(11):1572–1574.
   Google Scholar
• Mocroft A, Lundgren JD. Starting highly active antiretroviral therapy: why, when and response to HAART. J Antimicrob Chemother. 2004;54(1):10–13.
   PubMed Web of Science ®Google Scholar
• Floridia M, Bucciardini R, Ricciardulli D, et al. A random-ized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse tran-scriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20(1)1 1–19.
   Web of Science ®Google Scholar
• Garcia F, Romeu J, Grau I, et al. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. AIDS. 1999;13(17): 2377–2388.
   Google Scholar
• Ena J, Pasquau F. Once-a-day highly active antiretroviral therapy: a systematic review. Clin Infect Dis. 2003;36(9): 1186–1190.
   PubMed Web of Science ®Google Scholar
• Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 1999;13(14):1873–1880.
   PubMed Web of Science ®Google Scholar
• Matheron S, Descamps D, Boue F, et al. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther. 2003;8(2):163–171.
   PubMed Web of Science ®Google Scholar
• Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002 ;346 (26):2039–2046 .
   PubMed Web of Science ®Google Scholar
• GatheJ Jr, Badaro R, Grimwood A, et al. Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir.JAcquirlmmune Defic Syndr. 2002;31 (4):399–403.
   PubMed Web of Science ®Google Scholar
• Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (A1424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003;32(1):18–29.
   PubMed Web of Science ®Google Scholar
• Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, random-ized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003;17(18):2603–2614.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther. 2003;8(4):339–346.
   PubMed Web of Science ®Google Scholar
• Montaner JSG, Reiss P, Cooper DA, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS trial. JAMA. 1998;279(12):930–937.
   PubMed Web of Science ®Google Scholar
• van Leeuwen R, Katlama C, Murphy RL, et al. A random-ized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003;17(7):987–999.
   PubMed Web of Science ®Google Scholar
• French M, Amin J, Roth N, et al. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously un-treated HIV-1 infection: the OzCombo 2 study. HIV Clin Trials. 2002;3(3):177–185.
   PubMedGoogle Scholar
• Raffi F, Reliquet V, Ferre V, et al. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults. Antivir Ther. 2000;5(4):267–272.
   PubMed Web of Science ®Google Scholar
• Raffi F, Reliquet V, Francois C, et al. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-in-fected adults: preliminary safety and efficacy results. VIRGO Study Team. Antivir Ther. 1998;3\(suppl 4):57–60.
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther. 2002;7(2):81–90.
   PubMed Web of Science ®Google Scholar
• Nunez M, Soriano V, Martin-Carbonero L, et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a ran-domized, open-label study in HIV-infected naive individu-als. HIV Clin Trials. 2002;3(3):186–194.
   PubMedGoogle Scholar
• Garcia F, Knobel H, Sambeat MA, et al. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study. AIDS. 2000;14(16):2485–2494.
   PubMed Web of Science ®Google Scholar
• van Leth F, Phanuphak P, Ruxrungtham K, et al. Compari-son of first-line antiretroviral therapy with regimens includ-ing nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363(9417):1253–1263.
   PubMed Web of Science ®Google Scholar
• Johnson M, Peters B. Saquinavir/low-dose ritonavir: its use in HIV infection. AIDS Rev. 2003;5(1):44–51.
   PubMedGoogle Scholar
• Plosker GL, Scott Li. Saquinavir: a review of its use in boosted regimens for treating HIV infection. Drugs. 2003; 63(12):1299–1324.
   PubMed Web of Science ®Google Scholar
• Montaner JSG, Saag M, Barylski C, Siemon-Hryczyk P. FOCUS study: saquinavir qd regimen versus efavirenz qd regimen 24 week analysis in HIV infected patients. In: Program and abstracts of the 41st Interscience Confer-ence on Antimicrobial Agents and Chemotherapy (ICAAC); September 22–25, 2001; Chicago, IL. Abstract 1–670.
   Google Scholar
• Montaner JSG, Saag MS, Barylski C, Siemon-Hryczyk P. FOCUS study: saquinavir qd regimen versus efavirenz qd regimen 48 week analysis in HIV infected patients. In: Program and abstracts of the 42nd Interscience Confer-ence on Antimicrobial Agents and Chemotherapy; Sep-tember 27–30, 2002. San Diego, CA. Abstract H–167.
   Google Scholar
• Ananworanich J, Ruxrungtham K, Siangphoe U, et al. A prospective cohort study of efficacy and safety of 2 NRTIs plus once-daily ritonavir boosted-saquinavir hard gel cap-sules (SQV-HGC/r) at 24 weeks. In: Program and abstracts of the 15th International AIDS Conference; July 11–16, 2004; Bangkok, Thailand. Abstract TuPeB4469.
   Google Scholar
• Moore R, Keruly J, Gebo K, Lucas G. Improvement in virologic, immunologic, and clinical outcomes in clinical practice from 1996 to 2002. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2004; San Fransisco, CA. Ab-stract 558.
   Google Scholar
• Autar RS, Ananworanich J, Apateerapong W, Sankote J, et al. Pharmacokinetic study of saquinavir hard gel caps/ ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/ 100 mg twice-daily. J Antimicrob Chemother. 2004; 54(4):785–790.
   PubMed Web of Science ®Google Scholar